AP643A - Substituted benzylaminopiperidine compounds. - Google Patents

Substituted benzylaminopiperidine compounds. Download PDF

Info

Publication number
AP643A
AP643A APAP/P/1996/000850A AP9600850A AP643A AP 643 A AP643 A AP 643A AP 9600850 A AP9600850 A AP 9600850A AP 643 A AP643 A AP 643A
Authority
AP
ARIPO
Prior art keywords
compound
salts
trifluoromethyl
amino
methoxy
Prior art date
Application number
APAP/P/1996/000850A
Other languages
English (en)
Other versions
AP9600850A0 (en
Inventor
Kunio Satake
Yuji Shishido
Hiroaki Wakabayashi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP9600850A0 publication Critical patent/AP9600850A0/xx
Application granted granted Critical
Publication of AP643A publication Critical patent/AP643A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
APAP/P/1996/000850A 1995-08-24 1996-08-24 Substituted benzylaminopiperidine compounds. AP643A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB9500683 1995-08-24

Publications (2)

Publication Number Publication Date
AP9600850A0 AP9600850A0 (en) 1996-10-31
AP643A true AP643A (en) 1998-04-24

Family

ID=11004362

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1996/000850A AP643A (en) 1995-08-24 1996-08-24 Substituted benzylaminopiperidine compounds.

Country Status (41)

Country Link
US (1) US6506775B1 (es)
EP (2) EP1114817B1 (es)
JP (1) JP3084069B2 (es)
KR (1) KR100288673B1 (es)
CN (1) CN1153764C (es)
AP (1) AP643A (es)
AR (1) AR006305A1 (es)
AT (2) ATE208377T1 (es)
AU (1) AU702698B2 (es)
BG (1) BG64126B1 (es)
BR (1) BR9609989A (es)
CA (1) CA2227814C (es)
CO (1) CO4480738A1 (es)
CZ (1) CZ297543B6 (es)
DE (2) DE69631390T2 (es)
DK (2) DK0861235T3 (es)
DZ (1) DZ2086A1 (es)
ES (2) ES2211684T3 (es)
HR (1) HRP960386B1 (es)
HU (1) HU225480B1 (es)
IL (1) IL119078A (es)
IS (1) IS1947B (es)
MA (1) MA23961A1 (es)
MX (1) MX9801467A (es)
MY (1) MY114800A (es)
NO (1) NO310720B1 (es)
NZ (1) NZ308207A (es)
OA (1) OA10666A (es)
PE (2) PE20010700A1 (es)
PL (1) PL186773B1 (es)
PT (2) PT1114817E (es)
RO (1) RO119299B1 (es)
RU (1) RU2152930C2 (es)
SI (2) SI0861235T1 (es)
SK (1) SK282925B6 (es)
TN (1) TNSN96107A1 (es)
TR (1) TR199800300T1 (es)
TW (1) TW340842B (es)
UA (1) UA48981C2 (es)
WO (1) WO1997008144A1 (es)
YU (1) YU49122B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9706196A (es) * 1996-08-14 1998-02-28 Pfizer Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p.
TW426667B (en) * 1997-11-19 2001-03-21 Pfizer Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance P antagonists
US6777428B1 (en) 1999-02-10 2004-08-17 Eli Lilly And Company 5-HT1f agonist
JP2002544128A (ja) * 1999-05-06 2002-12-24 ファイザー・プロダクツ・インク 置換ベンゾラクタム化合物
RS49964B (sr) 1999-05-17 2008-09-29 Pfizer Products Inc., Postupak za dobijanje 2-fenil-3-aminopiridina,njegovih supstituisanih fenil derivata, i njegovih soli
HRP20010861A2 (en) 1999-05-21 2003-04-30 Pfizer Prod Inc 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
DK1095939T3 (da) * 1999-10-18 2004-04-13 Pfizer Prod Inc Fremgangsmåde til fremstilling af cykliske piperidinylaminomethyltrifluormethyletherforbindelser
JP2001172178A (ja) * 1999-10-25 2001-06-26 Pfizer Prod Inc 偏頭痛治療用のnk−1レセプターアンタゴニスト及びエレトリプタン
MXPA02004330A (es) 1999-11-03 2004-07-30 Albany Molecular Res Inc Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina..
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
KR100821410B1 (ko) 2000-07-11 2008-04-10 에이엠알 테크놀로지, 인크. 4-페닐 치환된 테트라하이드로이소퀴놀린 및 이의치료학적 용도
PE20020291A1 (es) * 2000-08-21 2002-04-17 Hoffmann La Roche Profarmacos para ligandos del receptor nmda
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (en) * 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
US6911544B2 (en) 2002-10-23 2005-06-28 Pfizer Inc. Process for the preparation of (S,S)-cis-2-phenyl-3-aminopiperidine
MXPA05011223A (es) 2003-04-18 2006-01-26 Lilly Co Eli Compuestos de (piperidiniloxi)fenilo, (piperidiniloxi)piridinilo, (piperidinilsulfanil)fenilo y (piperidinilsulfanil)piridinilo como agonistas 5-htif.
JP2008500382A (ja) * 2004-05-21 2008-01-10 ファイザー・プロダクツ・インク (+)−(2s,3s)−3−(2−メトキシ−5−トリフルオロメトキシベンジルアミノ)−2−フェニル−ピペリジンの代謝産物
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
KR101594898B1 (ko) 2005-07-15 2016-02-18 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
JP4611444B2 (ja) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤としてのアミド置換インダゾール
JP5319518B2 (ja) 2007-04-02 2013-10-16 Msd株式会社 インドールジオン誘導体
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
AU2009222122A1 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
US7951822B2 (en) 2008-03-31 2011-05-31 Kowa Company, Ltd. 1,3-dihydroisobenzofuran derivatives
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
AU2010247735B2 (en) 2009-05-12 2015-07-16 Albany Molecular Research, Inc. Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
AU2010247763B2 (en) 2009-05-12 2015-12-24 Albany Molecular Research, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
WO2010132437A1 (en) 2009-05-12 2010-11-18 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
PE20121172A1 (es) 2009-10-14 2012-09-05 Merck Sharp & Dohme Piperidinas sustituidas con actividad en la hdm2
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
EP3330377A1 (en) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
US9029341B2 (en) 2010-08-17 2015-05-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
AU2012245971A1 (en) 2011-04-21 2013-10-17 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP3525785B1 (en) 2016-10-12 2025-08-27 Merck Sharp & Dohme LLC Kdm5 inhibitors
EP3706747B1 (en) 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Prmt5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
US12173026B2 (en) 2018-08-07 2024-12-24 Merck Sharp & Dohme Llc PRMT5 inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000331A1 (en) * 1991-06-20 1993-01-07 Pfizer Inc. Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
WO1993001170A1 (en) * 1991-07-01 1993-01-21 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364943A (en) * 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
SK284565B6 (sk) * 1991-03-26 2005-06-02 Pfizer Inc. Spôsob prípravy substituovaných piperidínov
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0653208A3 (en) * 1993-11-17 1995-10-11 Pfizer Substance P antagonists for the treatment or prevention of sunburn.
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
US5886011A (en) 1995-03-27 1999-03-23 Hisamitsu Pharmaceutical Co., Inc. Piperidine derivatives as substance P antagonists
PT780375E (pt) * 1995-12-21 2002-12-31 Pfizer 3-¬(benzilo substituido em 5)amino|-2-phenilpiperidinas como antagonistas da substancia p
US5990125A (en) 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000331A1 (en) * 1991-06-20 1993-01-07 Pfizer Inc. Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
WO1993001170A1 (en) * 1991-07-01 1993-01-21 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles

Also Published As

Publication number Publication date
KR100288673B1 (ko) 2001-05-02
DK1114817T3 (da) 2004-04-26
UA48981C2 (uk) 2002-09-16
JPH10510554A (ja) 1998-10-13
PE1398A1 (es) 1998-02-27
BG64126B1 (bg) 2004-01-30
TW340842B (en) 1998-09-21
CO4480738A1 (es) 1997-07-09
PE20010700A1 (es) 2001-07-09
EP1114817A1 (en) 2001-07-11
ATE258166T1 (de) 2004-02-15
AU702698B2 (en) 1999-03-04
CN1193961A (zh) 1998-09-23
TNSN96107A1 (fr) 2005-03-15
TR199800300T1 (xx) 1998-06-22
CA2227814A1 (en) 1997-03-06
ATE208377T1 (de) 2001-11-15
RO119299B1 (ro) 2004-07-30
HUP9901159A3 (en) 2000-05-29
MX9801467A (es) 1998-05-31
IS4644A (is) 1997-12-30
IS1947B (is) 2004-10-13
CA2227814C (en) 2002-12-31
MA23961A1 (fr) 1997-04-01
KR19990044077A (ko) 1999-06-25
NO980751D0 (no) 1998-02-23
DZ2086A1 (fr) 2002-07-22
DE69631390D1 (de) 2004-02-26
EP0861235B1 (en) 2001-11-07
YU47896A (sh) 1998-12-23
AU5776996A (en) 1997-03-19
HRP960386A2 (en) 1998-04-30
DK0861235T3 (da) 2001-12-27
SI0861235T1 (en) 2002-04-30
CZ52198A3 (cs) 1999-01-13
DE69631390T2 (de) 2004-11-25
JP3084069B2 (ja) 2000-09-04
BG102288A (en) 1998-09-30
IL119078A0 (en) 1996-11-14
HRP960386B1 (en) 2002-04-30
IL119078A (en) 2003-11-23
PT861235E (pt) 2002-03-28
PL325332A1 (en) 1998-07-20
HK1014935A1 (en) 1999-10-08
EP0861235A1 (en) 1998-09-02
HUP9901159A2 (hu) 1999-07-28
AR006305A1 (es) 1999-08-25
MY114800A (en) 2003-01-31
SI1114817T1 (en) 2004-06-30
BR9609989A (pt) 1999-07-06
DE69616817D1 (de) 2001-12-13
RU2152930C2 (ru) 2000-07-20
CN1153764C (zh) 2004-06-16
HU225480B1 (en) 2006-12-28
NO980751L (no) 1998-02-23
NZ308207A (en) 1998-07-28
PL186773B1 (pl) 2004-02-27
SK282925B6 (sk) 2003-01-09
SK20798A3 (en) 1999-03-12
DE69616817T2 (de) 2002-04-04
ES2211684T3 (es) 2004-07-16
WO1997008144A1 (en) 1997-03-06
CZ297543B6 (cs) 2007-02-07
YU49122B (sh) 2004-03-12
ES2163017T3 (es) 2002-01-16
PT1114817E (pt) 2004-05-31
AP9600850A0 (en) 1996-10-31
US6506775B1 (en) 2003-01-14
NO310720B1 (no) 2001-08-20
OA10666A (en) 2002-11-25
EP1114817B1 (en) 2004-01-21

Similar Documents

Publication Publication Date Title
AP643A (en) Substituted benzylaminopiperidine compounds.
US5744480A (en) Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
EP0699199B1 (en) Heteroatom substituted alkyl benzylaminoquinuclidines as substance p antagonists
JP2500279B2 (ja) アザ二環式化合物、これを含有する医薬組成物及び治療のための使用方法
JPH0757748B2 (ja) 3−アミノピペリジン誘導体及び関連する窒素含有複素環化合物
US5332817A (en) 3-aminopiperidine derivatives and related nitrogen containing heterocycles
CA2193468C (en) 3-[(5-substituted benzyl)amino]-2-phenylpiperidines as substance p antagonists
US6329396B1 (en) Substituted benzylaminopiperidine compounds
US4705807A (en) Amine derivatives
JP3172461B2 (ja) サブスタンスpアンタゴニストとしての3−[(5−置換ベンジル)アミノ]−2−フェニルピペリジン
JP2822274B2 (ja) P物質拮抗剤としてのヘテロ原子置換アルキルベンジルアミノキヌクリジン類
US20050256162A1 (en) Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
HK1000247B (en) Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles